NDA 019797 · Azurity
Nulytely
Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride · Oral · Osmotic Laxative
Last checked: Nov 19, 2026Latest source record: May 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Apr 22, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
127
31 Phase 3, 9 recruiting
FAERS reports
248
151 serious, 30 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater. PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy in adults and pediatric patients aged 6 months or greater ( 1 )
Mechanism: The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 22, 1991 Original approval · Type 4 - New Combination Medication Guide
2 products under this application
- NULYTELY · POLYETHYLENE GLYCOL 3350 420GM/BOT; POTASSIUM CHLORIDE 1.48GM/BOT; SODIUM BICARBONATE 5.72GM/BOT; SODIUM CHLORIDE 11.2GM/BOT · FOR SOLUTION, ORAL · Prescription · TE AA
- NULYTELY-FLAVORED · POLYETHYLENE GLYCOL 3350 420GM/BOT; POTASSIUM CHLORIDE 1.48GM/BOT; SODIUM BICARBONATE 5.72GM/BOT; SODIUM CHLORIDE 11.2GM/BOT · FOR SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Polyethylene Glycol 3350" as an intervention, any sponsor and status, largest first.
- Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation RegimensPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT03298945 · 2,239 participants · Start Dec 13, 2018 · Primary completion Dec 30, 2023
Drug: Miralax-Gatorade Prep; Golytely · For: Colorectal Cancer
Sites: Philadelphia, Pennsylvania
- Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon CleansingPivotal-lookingCompleted
Parc de Salut MarAcademic, hospital or other
NCT04598880 · 1,180 participants · Start Nov 6, 2020 · Primary completion Apr 1, 2024
Drug: Polyethylene glycol + ascorbate; Sodium picosulfate + magnesium citrate · For: Colonic Diseases
Sites: Viladecans, Spain; Alava, Spain; Almería, Spain · 14 sites in all
- A Comparison of 5 Low Volume Bowel PreparationsPivotal-lookingCompleted
Gastroenterology Services, Ltd.Academic, hospital or other
NCT01719653 · 1,079 participants · Start Oct 2012 · Primary completion Sep 2014
Drug: MiraLAX; MoviPrep and 1 more · For: Bowel Preparation for Colonoscopy
Sites: Downers Grove, Illinois
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02938520 · 631 participants · Start Oct 27, 2016 · Primary completion Aug 30, 2018
Drug: Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Bakersfield, California; Long Beach, California · 108 sites in all
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT02951052 · 618 participants · Start Oct 28, 2016 · Primary completion May 29, 2018
Drug: Cabotegravir (CAB) tablet; Rilpivirine (RPV) tablet and 3 more · For: Infection, Human Immunodeficiency Virus; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 113 sites in all
- Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy PreparationPivotal-lookingCompleted
Gastroenterology Services, Ltd.Academic, hospital or other
NCT01063049 · 600 participants · Start Feb 2010 · Primary completion Feb 2011
Drug: Gatorade/Miralax; NuLytely and 2 more · For: Preparation for Colonoscopy
Sites: Downers Grove, Illinois
- Safety and Efficacy Study of CitraFleet (Sodium Picosulphate) as an Evacuating Treatment Prior to Colonoscopy.Pivotal-lookingCompleted
Laboratorios Casen-Fleet S.L.U.Industry
NCT01065857 · 547 participants (planned) · Start Jan 2010 · Primary completion Jun 2010
Drug: Sodium picosulphate, light magnesium oxide and anhydride citric acid.; Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate. · For: Subjects Undergoing a Complete Exploratory Diagnostic Colonoscopy for the First Time.
Sites: Barcelona, Spain; Córdoba, Spain; Granada, Spain · 15 sites in all
- A Safety Study of 3 Different Bowel Cleansing PreparationsPivotal-lookingCompleted
Braintree LaboratoriesIndustry
NCT01501513 · 541 participants · Start Dec 2011 · Primary completion Mar 4, 2013
Drug: PEG-3350 based bowel preparation; BLI800 approved preparation regimen and 1 more · For: Colonoscopy; Bowel Preparation; Endoscopy
Sites: Mobile, Alabama; Anaheim, California; Jacksonville, Florida · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting34
- nausea28
- drug ineffective14
- fatigue14
- pneumonia14
- chronic kidney disease13
- abdominal distension12
- renal failure12
- asthenia11
- constipation11
- diarrhoea11
- dyspnoea11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 17 |
| 2014 | 5 |
| 2015 | 16 |
| 2016 | 19 |
| 2017 | 24 |
| 2018 | 29 |
| 2019 | 23 |
| 2020 | 24 |
| 2021 | 7 |
| 2022 | 25 |
| 2023 | 9 |
| 2024 | 15 |
| 2025 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nulytely (Sodium Chloride/NaHCO3/KCl/PEG)
2024 spending
$619
Beneficiaries
32
32 claims
Per beneficiary
$19
$0.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,996 |
| 2021 | $145,943 |
| 2022 | $69,425 |
| 2023 | $2,220 |
| 2024 | $619 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- OTC polyethylene glycol 3350 and pharmacists' role in managing constipation.
Horn JR, Mantione MM, Johanson JF · J Am Pharm Assoc (2003) 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
Rahimi RS, Singal AG, Cuthbert JA, et al. · JAMA Intern Med 2014 · Comparative Study, Randomized Controlled Trial
- Efficacy, safety, and acceptability of polyethylene glycol 3350 without electrolytes vs magnesium hydroxide in functional constipation in children from six months to eighteen years of age: A controlled clinical trial.
Worona-Dibner L, Vázquez-Frias R, Valdez-Chávez L, et al. · Rev Gastroenterol Mex (Engl Ed) 2023 · Randomized Controlled Trial
- Polyethylene glycol 3350 plus electrolytes for pediatric chronic constipation: An open-label clinical study in Japan.
Gondo M, Nagata S, Shinbo K, et al. · Pediatr Int 2020 · Clinical Trial, Phase III, Multicenter Study
- High-dose polyethylene glycol-3350 and gatorade solutions for patients with previous inadequate bowel preparations for colonoscopy are safe and effective.
Gerard DP, Gerard SF, Raiser MW · BMC Gastroenterol 2023 · Clinical Trial
- Urinary excretion of polyethylene glycol 3350 during colonoscopy preparation.
Rothfuss KS, Bode JC, Stange EF, et al. · Z Gastroenterol 2006 · Clinical Trial
Sponsor: Azurity · Also marketed as Nulytely-Flavored
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.